The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...
The first cohort comprised individuals who started and continued either a GLP-1 receptor agonist or DPP-4 inhibitor for the first time between January 1, 2007, and December 31, 2020. The second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback